CutisPharma CEO Talks to Bloomberg About Compounding Market Hear CEO Neal Muni’s thoughts about changes to the compounding landscape in his interview with Bloomberg.
CutisPharma, Dr. Reddy's Laboratories Announce Partnership Joint development agreement will accelerate NDA filing and worldwide commercialization.
CutisPharma Announces Initiation of Manufacturing Operations Mass. Housing and Economic Development Secretary Jay Ash joins us to commemorate important milestone.
Benefits of FIRST®-Vancomycin Presented Stability of antimicrobial activity demonstrated in a scientific abstract presented at the 13th Biennial Congress of the Anaerobe Society of the Americas.
Superior stability of FIRST®-Vancomycin highlighted in peer-reviewed study. Compared to extemporaneously compounded vancomycin in study published in IJPC.
|Upcoming 2016 Trade Shows|
NACDS Total Expo
August 6–9 Boston, MA
National Pharmacy Purchasing Association
August 22–25 Las Vegas, NV